seragy Launches with €12 Million Financing to Advance Quantitative Biomarkers for Neurodegenerative Diseases

seragy holding GmbH

/ Key word(s): Financing

seragy Launches with €12 Million Financing to Advance Quantitative Biomarkers for Neurodegenerative Diseases

14.10.2026 / 10:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


seragy Launches with €12 Million Financing to Advance Quantitative Biomarkers
for Neurodegenerative Diseases

  • Development of quantitative biomarker strategies for proteopathies through seragy’s proprietary SeRAS® technology
  • Expansion of the company’s laboratory and analytical capabilities with funding from Commerzbank, the Mittelständische Beteiligungsgesellschaft (MBG), and the State of Lower Saxony
  • Separate funding from The Michael J. Fox Foundation provides support for a quantitative SeRAS-based assay for Parkinson’s disease

Hanover, Germany, October 14, 2026 – seragy holding GmbH (formerly Prosperodes GmbH), a biomarker strategy company focused on neurodegenerative diseases and other proteopathies, has secured €12 million in funding to accelerate the development of its SeRAS® platform (Seed Replication, Analysis and Subtyping) and expand its laboratory and analytical capabilities. The financing is backed by Commerzbank, the Mittelständische Beteiligungsgesellschaft (MBG), and the State of Lower Saxony.

Proteopathies – such as Alzheimer’s, Parkinson’s, and ALS – are among the greatest challenges in modern medicine. These diseases are characterized by pathological protein aggregation and display substantial molecular heterogeneity, often with multiple distinct disease subtypes within one indication. Current technologies often lack the ability to distinguish clinically relevant molecular patterns and quantify aggregation processes with the precision required for translational drug development.

Using its proprietary SeRAS technology, seragy develops quantitative, mechanism-relevant biomarkers that generate molecular fingerprints of pathological protein aggregation from patient samples. Unlike conventional seed amplification assays, which primarily provide binary detection without molecular resolution, these fingerprints will reveal quantitative biological changes and identify relevant subtypes of proteopathies. By translating aggregation biology into actionable biomarker insights, seragy will support pharmaceutical and biotechnology partners in developing more targeted therapeutic strategies from early discovery through clinical development.

“This financing provides the foundation for us to transform how pathological protein aggregation is measured and understood,” said Dr. Thorsten Lührs, Managing Partner for Strategy & Innovation and Co-Founder of seragy. “Together with our highly qualified interdisciplinary team, we will continue advancing SeRAS as a next-generation biomarker platform that makes aggregation processes measurable and biologically interpretable. Through our global collaborations with pharmaceutical and biotechnology partners, SeRAS provides insights informing therapeutic strategies and helps accelerate the development of effective treatments for patients with proteopathies. We thank Commerzbank, the MBG, and the State of Lower Saxony for their trust and commitment to our technology.”

With this combination of debt financing, equity capital, and public funding, seragy will accelerate the further development and application of its SeRAS technology by expanding its laboratory and analytical capabilities and growing its team in Hanover. At the same time, the company will strengthen its presence in European and international markets and further expand its collaborations with pharmaceutical and biotechnology companies to provide translational biomarker strategies across early-stage discovery, preclinical, and clinical development.

“seragy combines scientific excellence and a clear vision with a highly innovative technology platform for addressing a critical challenge in developing treatments for neurodegenerative diseases,” said Marc Hülsbruch, Chairman of the Management Board for Small-Business Customers in Lower Saxony at Commerzbank AG. “By advancing cutting-edge technologies that ultimately help patients, companies like seragy demonstrate how a strong innovation ecosystem in Lower Saxony can contribute to the future of healthcare worldwide.”

Separately, seragy is one of five recipients of funding from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through its Seed Amplification Assay Innovation Program. The grant supports the development and evaluation of a quantitative biomarker assay for Parkinson’s disease and underscores the potential of the SeRAS technology to advance the development of translational biomarkers in neurodegenerative diseases.

About seragy holding GmbH

seragy holding GmbH (formerly Prosperodes GmbH) is a biomarker strategy company based in Hanover, Germany. Through its wholly owned subsidiary seragy analytics GmbH and using its proprietary SeRAS® platform, the Company develops quantitative translational biomarkers for proteopathies – diseases driven by protein aggregation – including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). Seragy’s strategy is to generate molecular fingerprints of protein aggregates, which will reveal disease-specific subtypes and enable quantification of biological changes. The goal is to accelerate the development of targeted therapies through deep insights into disease mechanisms and to improve the chances of success for new drugs through precise biomarkers.

Founded in 2022 as Prosperodes GmbH, seragy holding GmbH is led by Dr. Christiane Ritter and Dr. Thorsten Lührs, two scientists with nearly three decades of expertise in protein aggregation research, alongside Arne Ungruh, an experienced business and finance leader. The holding company owns the intellectual property, acts as the licensor and consolidates central holding functions, while operational activities, particularly services and projects for partner companies, are carried out by seragy analytics GmbH. The company is supported by The Michael J. Fox Foundation, Commerzbank AG, Mittelständische Beteiligungsgesellschaft Niedersachsen (MBG), and the State of Lower Saxony, among others.

For more information, visit: https://seragy.com/

About SeRAS®

SeRAS® (Seed Replication, Analysis, and Subtyping) is seragy’s proprietary technology platform for the highly sensitive analysis of pathological protein aggregates. As a further development of classical seed amplification assays, SeRAS combines seeding-based biochemistry with high-sensitivity optics, automated data analysis, software algorithms, and micromechanical components. At the heart of the platform is the MetisOne® Analyzer, which has been designed to enable quantitative and reproducible measurements of protein aggregates from patient samples. Unlike conventional seed amplification assays, which primarily provide qualitative detection, SeRAS has been developed to generate quantitative molecular fingerprints that can be used to characterize aggregation patterns, distinguish molecular subtypes, and track biological changes over the course of a disease. The platform is designed for the development of translational biomarkers, from early drug discovery through preclinical and clinical development.

 

seragy Contact:
seragy holding GmbH                                                                 
info@seragy.com
Media Contact:
MC Services AG
Dr. Cora Kaiser / Dr. Regina Lutz
Tel.: +49 (0)89 210 228 0
E-Mail: seragy@mc-services.eu


14.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


2415212  14.10.2026 CET/CEST

MindMaze Therapeutics Reports New Home-Based Rehabilitation Results Ahead of MindMotion Lite Launch

MindMaze Therapeutics Holding SA

/ Key word(s): Study results

MindMaze Therapeutics Reports New Home-Based Rehabilitation Results Ahead of MindMotion Lite Launch

14.10.2026 / 07:00 CET/CEST


MindMaze Therapeutics Reports New Home-Based Rehabilitation Results Ahead of MindMotion Lite Launch

Multi-site program demonstrates threefold increase in rehabilitation training dose, with 84% delivered independently and significant improvements across functional measures

Geneva, Switzerland – October 14, 2026 – MindMaze Therapeutics (SIX: MMTX), a global leader in scalable precision neurotherapeutics, today announced new real-world evidence from a multi-site program conducted with Vibra Healthcare, presented yesterday at the American Congress of Rehabilitation Medicine (ACRM) in Washington, DC.

The program demonstrated that home-based rehabilitation using MindMotion increased total motor-training dose by a median factor of three compared with usual outpatient therapy alone. 84% of active training was completed independently, without direct therapist supervision. Participants also showed statistically significant improvements in functional independence, balance, mobility and cognition, alongside high patient satisfaction.

Building on previously reported inpatient results with Vibra Healthcare, the findings further support MindMaze Therapeutics’ strategy to extend high-dose, high-intensity neurorehabilitation into patients’ homes. This is particularly relevant to the Company’s upcoming launch of MindMotion Lite, expected by year-end 2026. Recently announced, the tablet-based solution is designed to deliver the full range of MindMotion GO neurotherapeutic activities with substantially reduced hardware requirements, simplifying home deployment and supporting broader adoption by healthcare providers.

“Earlier this year, we showed that MindMaze’s high-dose, high-intensity therapy, integrated into inpatient rehabilitation, delivers superior functional outcomes in a resource-efficient way,” said Zach Henderson, CEO of MindMaze Therapeutics. “Now, we are demonstrating that this value can extend into the home to address a well-recognized gap in care once patients leave the clinic, in line with the 2026 AHA/ASA Guideline for Adult Stroke Rehabilitation and Recovery. These results, combined with our upcoming MindMotion Lite tablet-based solution, will help make high-quality neurotherapeutics more accessible. Together, these milestones bring us closer to our mission of making neurotherapeutics available at scale.”

Study Design and Results
The retrospective, multi-site quality improvement program evaluated 177 rehabilitation episodes involving 172 adults with a range of neurological conditions, primarily stroke, across four Vibra Healthcare outpatient sites, without a control group. Participants followed an eight-week home-training program using MindMotion GO, with an optional four-week extension and periodic therapist supervision.

Key findings included:

  • Training dose: Patients completed an average of 174 minutes of active training per week, with 84.4% delivered asynchronously. The additional home training increased total motor-training dose by a median factor of 3.0 compared with usual outpatient therapy alone, based on published assumptions for active practice during usual care.
  • Feasibility and engagement: 92.7% successfully completed home setup, while 80.2% achieved the predefined minimum training exposure. Among surveyed participants, 83.8% of satisfaction ratings were positive.
  • Functional outcomes: Statistically significant pre–post improvements were observed in independence (Barthel Index: +10.4 points), balance (Berg Balance Scale: +10.5 points), cognition (SLUMS: +3.4 points) and mobility (Timed Up and Go: −8.8 seconds) among participants with available paired assessments.

The full poster, High-Dose, Home-Based Neurorehabilitation Using Gamified Technology: A Multi-Site Quality Improvement Program, is available at mindmazetherapeutics.com/mindmaze-platform/clinical-evidence.

About MindMaze Therapeutics
MindMaze Therapeutics (SIX: MMTX) is a global leader in scalable, precision neurotherapeutics, dedicated to redefining the recovery trajectory for patients around the world. By integrating advanced software, proprietary sensors, and AI-driven data analytics, MindMaze Therapeutics provides a seamless continuum of care from the acute hospital phase to outpatient treatment to home-based therapy. The company’s FDA-listed and CE-marked products are designed to address the systemic shortage of specialized clinicians, offering scalable, reimbursable solutions for stroke, Parkinson’s disease, and other neurological disorders. With an extensive library of rigorous clinical validation, MindMaze Therapeutics is operationalizing the future of neurorestorative medicine. For more information, visit www.mindmazetherapeutics.com.

Media & Investor Contacts
Jeremy Meinen, Chief Financial Officer
ir@mindmazetherapeutics.com

DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as “believe,” “assume,” “expect,” “intend,” “may,” “could,” “will,” or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. This communication is provided as of the date hereof, and MindMaze Therapeutics undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.


Additional features:

File: Press release_MindMaze_Home-Based Rehabilitation Results


End of Media Release


Language: English
Company: MindMaze Therapeutics Holding SA
Avenue de Secheron 15
1202 Geneva
Switzerland
Phone: +41 22 545 11 16
Fax: +41 22 545 11 17
E-mail: ir@mindmazetherapeutics.com
Internet: www.mindmazetherapeutics.com
ISIN: CH1251125998
Listed: SIX Swiss Exchange
EQS News ID: 2415188

 
End of News EQS News Service

2415188  14.10.2026 CET/CEST

Lonza Upgrades Organic Growth Model and Mid-term Financial Ambitions at Capital Markets Day; Q3 2026 In Line with Expectations

  • With the transformation into a focused, pure-play CDMO1 complete, and operational and financial performance strengthened, Lonza upgrades its Organic Growth Model2 and resulting mid-term financial ambitions.
  • The model entails low-teens (10-13%) organic CER sales growth on average over time, CORE EBITDA growth ahead of sales growth, an upgraded ambition to reach a CORE EBITDA margin in the high thirties in the mid-term, driving ROIC3 up to two to three times WACC4, and an improving FCF conversion5 on average over time.
  • Q3 2026 Qualitative Update: Lonza performed well and in line with expectations across all Business Platforms, and confirms its Full-Year 2026 Outlook, which was upgraded in H1 2026.

Basel, Switzerland, 14 October 2026 – At its Capital Markets Day in Vacaville, California, Lonza reports progress of its One Lonza Strategy to deliver long-term, profitable, above-market growth. In less than two years, Lonza has completed its transformation into a pure-play CDMO, following the exit6 of the Capsules & Health Ingredients business and further divestments. Based on stronger operational and financial performance, successful execution of growth projects and attractive future market opportunities, Lonza upgrades its Organic Growth Model. 

Wolfgang Wienand, CEO, Lonza, commented: “Lonza performed well in Q3 2026 and we continued to successfully execute our One Lonza Strategy. The transformation into a pure-play CDMO has created a stronger, more integrated global organization that is delivering for our customers across all Business Platforms. The power of the Lonza Engine and the improvements we are bringing to the business further strengthen our confidence in our Organic Growth Model and our ability to improve margin faster over time. We continue to significantly grow, expand profit margins and returns, increase cash generation, and allocate capital with discipline. It is this highly differentiated model that will drive sustainable long-term value creation for our customers and their patients, our shareholders and our people at One Lonza.”

Lonza’s Organic Growth Model

As a structural growth compounder, Lonza delivers resilient and repeatable above-market organic sales growth, high and further increasing profit margins and improving cash generation which funds investments into future growth at high returns to deliver sustainable long-term value to its shareholders.

Maturing high-return growth projects, improvements in operational, commercial and CapEx7 performance, and continued discipline in overhead costs are progressing well. Based on this, Lonza upgrades its Organic Growth Model of low-teens organic CER sales growth on average over time with an acceleration of the CORE EBITDA margin expansion, now reaching high thirties in the mid-term. It also expands the model to include a mid-term ROIC ambition of two to three times today’s WACC and an improving FCF conversion on average over time, reflecting its disciplined investment approach and overall greater capital efficiency. Unchanged, organic CapEx  is expected to fluctuate around mid-to-high teens percentage of sales, while Lonza remains committed to a progressive8 dividend distribution, all in line with its Capital Allocation Framework first shared in 2024. 

Q3 2026 qualitative business update

In Q3 2026, Lonza continued to perform well, in line with expectations across all Business Platforms. Lonza reiterates its Full-Year 2026 Outlook, as upgraded after H1 2026, of 11–12% CER sales growth and a CORE EBITDA margin of 33–34%. The company also reiterates its expectation of a negative FX impact of approximately 2% to 3% on 2026 sales growth.

Q3 performance in Capsules & Health Ingredients was also in line with expectations, with Lonza continuing to expect mid-single-digit CER sales growth and further CORE EBITDA margin expansion for Full-Year 2026.

About Vacaville

The Capital Markets Day is being held at Lonza’s Vacaville facility, acquired in 2024 from Roche. It is the company’s largest Integrated Biologics site for the commercial manufacture of complex biologics. During the investor event, management will share insights into Lonza’s Integrated Biologics Business Platform, which combines scientific, technological and manufacturing capabilities in an industry-leading end-to-end9 offering. 

The Capital Markets Day 2026 presentation is available to download here. To join the live webcast on 14 October 2026 at 09:00 PT / 18:00 CEST, please register here. 

Ad hoc: Evotec announces preliminary nine-months 2026 results above market expectations, reaffirming full-year 2026 guidance

Evotec SE / Key word(s): Forecast / Other

Ad hoc: Evotec announces preliminary nine-months 2026 results above market expectations, reaffirming full-year 2026 guidance

13-Oct-2026 / 22:37 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.

The issuer is solely responsible for the content of this announcement.


Ad hoc: Evotec announces preliminary nine-months 2026 results above market expectations, reaffirming full-year 2026 guidance
 

Hamburg, Germany – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced preliminary unaudited financial results for first nine months of 2026. Full financial results for the third quarter and the first nine months of 2026 will be published on November 5, 2026, as scheduled.

Based on preliminary figures, Evotec expects Group revenues for the first nine months of 2026 of approximately €465.0 million and adjusted Group EBITDA of approximately -€42.8 million. These figures are above current market expectations, with the variance driven largely by the phasing of consensus estimates.

Evotec reaffirms its full-year 2026 guidance, which projects Group revenues of approximately €570 to €610 million (€595 to €635 million at CER) and adjusted Group EBITDA of approximately -€70 to -€105 million (-€60 to -€90 million at CER).
 

– End of the ad hoc release –
 

Contact: Dr. Sarah Fakih, EVP Head of Global Communications and Investor Relations, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49 (0) 151 7068 8784 (m), sarah.fakih@evotec.com

End of Inside Information


13-Oct-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard), Tradegate BSX; Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; Nasdaq
LEI Code: 529900F9KI6OYITO9B12
EQS News ID: 2415242

 
End of Announcement EQS News Service

2415242  13-Oct-2026 CET/CEST

Eckert & Ziegler and TerThera Sign Supply Agreement to Bring Next-Generation GMP Terbium-161 Radiopharmaceutical Therapies to Brazilian Patient

Eckert & Ziegler SE

/ Key word(s): Contract

Eckert & Ziegler and TerThera Sign Supply Agreement to Bring Next-Generation GMP Terbium-161 Radiopharmaceutical Therapies to Brazilian Patient

13.10.2026 / 14:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


Berlin/Breda, 13 October 2026. Eckert & Ziegler Brazil, a regional subsidiary of the global nuclear medicine group Eckert & Ziegler SE (ISIN DE0005659700, TecDAX), and TerThera announced today the signing of a strategic supply agreement for the precursor Terbium-161.

Under the terms of the agreement, TerThera will supply its GMP-compliant non-carrier-added (n.c.a.) Terbium-161 (Tb-161) to Eckert & Ziegler Brazil. This partnership establishes a critical and reliable supply chain for the innovative isotope in South America, directly providing Brazilian patients access to the next generation of radioligand therapies. Moreover, the availability of GMP-grade Tb-161 will allow local pharmaceutical developers and clinical institutions to investigate the combination of Tb-161 with novel peptides, antibodies, and FAP-inhibitors to target a broad spectrum of oncological indications. The agreement, between Eckert & Ziegler Brazil and TerThera, will bring the next generation of Radioligand Therapy (RLT) to Brazil and allow access to a novel radiopharmaceutical for cancer healthcare.

Terbium-161, a carrier free lanthanide produced by neutron activation, is a highly promising radionuclide for Radioligand Therapy (RLT) exhibiting comparable chemical characteristics to known radiolanthanides that has the potential, due to highest addition of Auger electronic emission with a higher linear energy transfer, to improve anti-tumor capabilities for primary and (micro)metastasized cancers. The latest clinical results have shown a promising and effective anti-tumor response, even after treatment stops of conventional medicine, providing for a new therapy option by depositing a highest but localized tumor dose with limited impact on healthy tissue.

Expanding Local Theranostic Infrastructure

“It is a great milestone that after six years of absence we are back in Brazil with a potentially better radionuclide,” said Philippe van Overeem, CEO of TerThera. “Having supplied Lutetium-177 to Brazil for almost two decades, I know firsthand the passion and capability of the local nuclear medicine community. Returning to this market with GMP-grade Terbium-161 allows us to build on that legacy and give Brazilian doctors and researchers a powerful, next-generation tool to treat micro-metastases and complex tumors more effectively.”

The agreement leverages Eckert & Ziegler’s robust presence in Latin America, combining TerThera’s unique isotope production capabilities with a powerful regional distribution and manufacturing network.

“We are proud to partner with TerThera to bring this highly promising isotope to South America,” stated Fabrício Diel, the Managing Director of Eckert & Ziegler Brazil. “Integrating Terbium-161 into our portfolio perfectly aligns with our mission of “Contributing to saving lives” and our goal to expand local access to strategic theranostic solutions. By combining this premium radionuclide with advanced targeting agents here in Brazil, we are shortening the supply chain and opening new clinical horizons for oncology patients across the region.”

About Eckert & Ziegler
Eckert & Ziegler SE, with more than 1,100 employees, is THE leading independent radioisotope supplier and a specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
www.ezag.com

About TerThera BV
TerThera is a radionuclide production focused company based in The Netherlands. The founders and the staff of TerThera have decades of experience in the nuclear medicine industry and are giving their full focus on the production of the innovative radionuclide Terbium-161 (Tb-161). TerThera is building a global platform to meet the growing demand for radionuclides in oncology and nuclear medicine.
www.terthera.com

Your contact:
Eckert & Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com 


13.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Eckert & Ziegler SE
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-0
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX, TecDax,
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate BSX
LEI Code: 391200EUDABLUKXCKG48
EQS News ID: 2414828

 
End of News EQS News Service

2414828  13.10.2026 CET/CEST

NVision Deploys POLARIS at UCLouvain to Advance Cancer Metabolism Research

NVision Quantum

/ Key word(s): Miscellaneous

NVision Deploys POLARIS at UCLouvain to Advance Cancer Metabolism Research

13.10.2026 / 10:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


NVision Deploys POLARIS at UCLouvain to Advance Cancer Metabolism Research

●  Installation at UCLouvain’s NEST imaging platform will support research into treatment response and resistance in melanoma, triple-negative breast cancer and metastatic disease

ULM, Germany and BRUSSELS, Belgium, October 13, 2026 – NVision, a quantum technology company, today announced the deployment of its POLARIS quantum-enhanced MRI platform at UCLouvain’s Nuclear and Electron Spin Technologies (NEST) imaging platform in Belgium. Researchers will use the system to study cancer metabolism in preclinical models of melanoma, triple-negative breast cancer and metastatic disease, with an initial focus on identifying metabolic changes associated with treatment response and resistance.

The installation marks the latest expansion of NVision’s growing network of quantum-enhanced MRI research sites. In recent weeks, new POLARIS systems have also been deployed at IBEC in Barcelona and the University of Antwerp through the EU-funded Q-AID initiative, following NVision’s deployment at Hokkaido University in Japan. NVision is working toward approximately 20 POLARIS installations across Europe, North America and Asia by early next year.

The expansion comes as European research programs continue to advance quantum-enhanced metabolic imaging toward broader research and clinical use. In September, the German Federal Ministry of Research, Technology and Space extended the  QuE-MRT project by two years until August 2028, bringing the project volume to nearly €20 million. Together, these initiatives are helping put quantum-enhanced MRI into the hands of researchers investigating how metabolism can reveal new information about disease and treatment response.

“UCLouvain brings together exactly the kind of scientific expertise and infrastructure that can push metabolic imaging into new areas of cancer research,” said Prof. Myriam Chaumeil, Head of Research at NVision. “Our goal with POLARIS is to make quantum-enhanced MRI accessible to leading research teams so they can focus on the biological questions that matter. UCLouvain is an important step in this vision, with expertise in hyperpolarized 13C imaging and preclinical cancer models spanning melanoma, triple-negative breast cancer and metastatic disease. Their work will use metabolic imaging to reveal how tumors adapt to therapy, identify early markers of treatment response, and uncover metabolic changes associated with resistance, with NVision providing ongoing scientific and technical support throughout the studies.”

UCLouvain’s NEST platform combines a broad range of magnetic resonance technologies, including MRI, nuclear magnetic resonance (NMR), electron paramagnetic resonance (EPR) and hyperpolarization. This combination allows researchers to study multiple aspects of the tumor microenvironment and cancer biology within a single research environment.

POLARIS adds an automated, standardized approach to parahydrogen-induced polarization, or PHIP, a method of hyperpolarization that boosts the MRI signal of metabolic molecules by more than 10,000 times. The system produces hyperpolarized metabolic imaging agents in approximately three minutes, enabling researchers to visualize metabolic processes in real time using standard MRI systems.

At UCLouvain, researchers will initially use POLARIS to assess metabolic shifts across different cancer models as a surrogate for long-term markers for treatment response and resistance. The aim is to identify metabolic biomarkers that could provide an earlier indication of whether a therapy is working, while also uncovering metabolic vulnerabilities that could potentially be targeted therapeutically.

“The future of cancer monitoring may depend on our ability to capture the biology behind treatment response, revealing changes in tumor metabolism beyond glucose uptake, and the microenvironment before conventional imaging can detect them,” said Prof. Bénédicte Jordan of UCLouvain and Academic Lead of the NEST platform.

The first studies will focus on melanoma, triple-negative breast cancer and metastatic disease in preclinical models. By combining POLARIS with the complementary magnetic resonance capabilities already available through NEST, the UCLouvain team will be able to investigate changes in tumor metabolism alongside other characteristics of the tumor microenvironment.

The deployment is part of NVision’s broader effort to establish a distributed research network around quantum-enhanced metabolic MRI. Across its growing installed base, researchers are using POLARIS to investigate disease biology in oncology, cardiology, neurology, and immunology. This includes studying disease progression and treatment response, while building the scientific evidence and workflows needed to advance metabolic imaging toward wider clinical use.

About NVision Quantum Technologies

NVision is a quantum technology company focused on healthcare, with deep expertise in engineering and controlling the quantum properties of organic molecules. This approach underpins both its POLARIS platform, which enables real-time measurement of metabolism on standard MRI systems, and its quantum computing platform, Photonic Integrated Quantum Circuits (PIQC, pronounced “Pixie”). Together, these capabilities are helping bridge the gap between understanding disease and delivering effective therapies. Founded in 2015 and headquartered in Ulm, Germany, NVision is backed by Playground Global, Entrée Capital, Matterwave/b2venture, Lauder Partners, Pathena Investments, The European Investment Bank and others. Learn more at nvision-quantum.com.

 
Company Contact:
 
                               Media Contact:
Leah Wiedenmann                                Dr. Cora Kaiser
NVision Quantum Technologies                                MC Services AG
leah.wiedenmann@nvision-quantum.com                                nvision@mc-services.eu
 


13.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


2414242  13.10.2026 CET/CEST

PL BioScience Launches PL Synergy to Simplify and Standardize MSC Research

PL BioScience GmbH

/ Key word(s): Product Launch

PL BioScience Launches PL Synergy to Simplify and Standardize MSC Research

13.10.2026 / 10:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


PL BioScience Launches PL Synergy to Simplify and Standardize MSC Research

Two-component culture kit combines PL Base and PL Boost for streamlined xeno-free MSC expansion.

Aachen, Germany, 13 October 2026 – PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion and development, today announced the launch of PL Synergy, a research-grade culture kit designed to simplify and standardize the expansion of Mesenchymal Stromal Cells (MSCs) in academic and translational research.

PL Synergy combines two components optimized for joint use: PL Base, a custom-formulated basal medium developed for MSC growth and proliferation, and PL Boost, a proprietary supplement that eliminates the need for Fetal Bovine Serum (FBS). The two-component system requires no additional preparation and provides researchers with a streamlined, optimized MSC culture workflow.

By removing the need for performance and compatibility assessment of independent media and supplements, PL Synergy is designed to simplify laboratory protocols while reducing the lot-to-lot variability associated with animal-derived serum. The xeno-free system is enhanced for MSC viability and kinetics compared with standard α-MEM + FBS formulations, supporting more consistent and reproducible research workflows.

“MSC researchers need culture workflows that combine performance with consistency and ease of use,” said Dr. Hatim Hemeda, CEO of PL BioScience. “PL Synergy brings together two components designed to work as one system, reducing the burden associated with technical validation, while providing researchers with a straightforward, xeno-free option for MSC expansion. With this launch, we are expanding the tools available to academic and translational researchers working to generate more reliable and reproducible results by using a single, optimized system.”

PL Synergy is intended for academic research laboratories conducting MSC studies, biotechnology companies developing cell culture models for mechanistic research or drug screening, and regenerative medicine researchers working in early and pre-clinical research. The kit is supplied jointly as PL Base and PL Boost and is intended for Research Use Only.

For more information about PL Synergy and its potential to support streamlined MSC research workflows, meet the PL BioScience team at BIO-EUROPE Cologne, on November 9-11, at the BIO.NRW booth (8-50). We look forward to discussing this latest innovation and exploring opportunities for collaboration.

 

About PL BioScience:

PL BioScience GmbH, a life science company located in Aachen, Germany, specializes in the production and development of Human Platelet Lysate (HPL). The company has pioneered proprietary technology to produce fully artificial HPL, allowing for a fully lab-made, scalable supply of HPL. PL BioScience currently offers a comprehensive portfolio of donor-derived, natural HPL products tailored for a range of applications – the ELAREM™platform. From academic and preclinical research to cell therapy and biopharmaceutical manufacturing, ELAREM™ ensures seamless translations of regenerative medicine breakthroughs – from the lab to patients in need. The company’s latest addition, PL Synergy, is a research-grade, xeno-free two-component culture kit — combining PL Base basal medium with the PL Boost supplement pack — designed to simplify Mesenchymal Stromal Cell expansion workflows and support MSC viability and proliferation without the need for FBS. PL BioScience is the only company worldwide holding a patent for the gamma-irradiation of HPL, covering the manufacturing process for ELAREM™ Ultimate-FD PLUS.

For more information on PL BioScience and the ELAREM™ platform, visit: https://www.pl-bioscience.com/

About Human Platelet Lysate:

Human Platelet Lysate (HPL) is an innovative, human-derived cell culture supplement used to support the growth and expansion of cells in research and clinical development, particularly in cell therapy, stem cell, and regenerative medicine applications. It is produced from donated human blood platelets that are no longer suitable for transfusion and would otherwise be discarded – making it a sustainable and resource-efficient alternative to traditional cell culture supplements.

In cell culture, HPL provides essential growth factors and nutrients that promote healthy, robust cell proliferation. Compared to conventional products such as Fetal Bovine Serum (FBS), which is harvested from unborn calves, HPL delivers more consistent results in cell growth, is free from animal-derived pathogens, and aligns with the increasing demand for animal-free and ethically responsible laboratory practices.

ELAREM™, PL BioScience’s line of xeno-free HPL products, can be used from early-stage research to the production of cell-based therapies under Good Manufacturing Practice (GMP) conditions for the treatment of patients.

Contact:

Dr. Hatim Hemeda, CEO
PL BioScience GmbH
+49(0)24195719-100
info@pl-bioscience.com

Media contact:
MC Services AG
Raimund Gabriel, Dr. Regina Lutz
+49 (0)89 210 228 0

U.S.: Catherine Featherston
+1-203-444-4393
E-Mail: pl-bioscience@mc-services.eu

 


13.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: PL BioScience GmbH
Auf der Hüls 184-186
52068 Aachen
Germany
E-mail: info@pl-bioscience.com
Internet: www.pl-bioscience.com
EQS News ID: 2414374

 
End of News EQS News Service

2414374  13.10.2026 CET/CEST

Mursla Bio Publishes Peer-Reviewed Validation of Tissue-Specific Extracellular Vesicle Platform for Liquid Biopsy

Mursla Bio Publishes Peer-Reviewed Validation of Tissue-Specific Extracellular Vesicle Platform for Liquid Biopsy




Mursla Bio Publishes Peer-Reviewed Validation of Tissue-Specific Extracellular Vesicle Platform for Liquid Biopsy

  • Study published in Journal of Extracellular Vesicles validates platform for new class of liquid biopsy: multiomic disease biology of living cells from a chosen tissue, starting with the liver
  • Platform underpins FDA Breakthrough Device-designated EvoLiver™ and precision medicine programs with pharmaceutical partners

CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Mursla Bio, a precision medicine and diagnostics company built on tissue-specific extracellular vesicles (TS-EVs), today announced publication of a peer-reviewed study in the Journal of Extracellular Vesicles (impact factor 21.7), the founding journal of the International Society for Extracellular Vesicles. This validates the TS-EV platform for a new class of liquid biopsy: the multiomic disease biology of living cells in a chosen tissue, read from blood, starting with the liver.


In this study, which builds on work first released as a preprint in June 2025, Mursla Bio’s NEXPLOR technology selectively enriched hepatocyte-derived EVs (h-EVs) over EVs from other tissues (lung, kidney, breast, adipose and muscle) and from the blood cells that dominate plasma. The multiomic content of h-EVs was analyzed against bulk EV preparations of the same clinical plasma samples, each under 2 mL, from patients with hepatocellular carcinoma (HCC) or cirrhosis and from healthy donors.

H-EVs accessed a different part of the hepatocyte proteome, identifying 57% more proteins than those bulk EVs, with better reproducibility. Bulk EVs were dominated by the plasma proteins the liver secretes, such as albumin, while h-EVs were enriched in the internal machinery of hepatocytes: membrane, cytosolic and mitochondrial proteins, including EV-defining markers1. The h-EV fraction revealed 86 proteins uniquely detected or significantly increased in liver disease against healthy donors, compared with 4 unique proteins and no significant differential signal in bulk EVs. These 86 reflected what cirrhosis and HCC shared: fibrosis, disordered fat metabolism and inflammation. Comparing HCC with cirrhosis, the h-EV fraction resolved HCC-defining proteins, and a wider set of proteins that cohered as a network. Paired bulk EVs yielded neither.

Small-RNA sequencing supported a similar conclusion in a second molecular layer. In the same comparison, the h-EV fraction yielded fewer differentially expressed microRNAs than paired bulk EVs, yet only the h-EV microRNAs mapped to HCC signaling, while the bulk set mapped to a more generalized inflammatory response. The same h-EVs were present in the bulk EV preparation, suggesting that the lack of tissue specificity holding back microRNAs as liquid biopsy biomarkers2 could be overcome.

The NEXPLOR technology described in the manuscript is a core component of Mursla Bio’s broader TS-EV platform. The hepatocyte panel is Mursla Bio’s first; the discovery and orthogonal validation route behind it is designed to extend to other tissues, and further panels are in development.

The platform has wide applications across clinical diagnostics, from disease surveillance to molecular residual disease (MRD), and precision medicine, including patient stratification, pharmacodynamic biomarkers and companion diagnostics.

Dr Tomás Dias, Chief Scientific Officer of Mursla Bio, said: “EVs are released by virtually every tissue into the bloodstream. They carry health and disease markers that can be traced back to their origin, much as a tissue biopsy would. To our knowledge, this is the most comprehensive validation to date of a platform for tissue-specific EV isolation from human plasma.”

Pierre Arsène, Founder and CEO of Mursla Bio, added: “Much of liquid biopsy has focused on measuring more analytes. Our thesis is that biological context matters as much as analytical depth. That is the foundation of EvoLiver and of the precision medicine programs we are building with pharma partners.”

  1. Tissue-specific isolation of hepatocyte extracellular vesicles from human plasma enables tissue-resolved proteomic and miRNA profiling, Journal of Extracellular Vesicles, 2026; 15:e70372. https://doi.org/10.1002/jev2.70372
  2. MicroRNAs in oncology: a translational perspective in the era of AI, Nature Reviews Clinical Oncology, 2026.

Contacts

Media contact
Dr Ben Rutter
Zyme Communications
Tel: +44(0)7920 770 935
Email: ben.rutter@zymecommunications.com

Undecimal Bio launches with $18 million oversubscribed Seed financing to address ‘liver trap’ in siRNA therapeutic delivery

Undecimal Bio launches with $18 million oversubscribed Seed financing to address ‘liver trap’ in siRNA therapeutic delivery




Undecimal Bio launches with $18 million oversubscribed Seed financing to address ‘liver trap’ in siRNA therapeutic delivery

  • A spin-out focused on AI-enabled decoding of the deliverome
  • Proprietary synthetic biology platform identifies conjugates that target RNA medicines beyond the liver, with initial focus on renovascular disease
  • Round co-led by 4BIO Capital and IQ Capital, with participation from Verve Ventures, Harel Tech, Entree Capital, Kerna Ventures and Saras Capital

CAMBRIDGE, England & TEL AVIV, Israel–(BUSINESS WIRE)–Undecimal Bio (“Undecimal”), a platform biotechnology company advancing targeted delivery of siRNA therapeutics, today announced an oversubscribed $18 million USD seed financing. The Company, a spin-out from Eleven Therapeutics, will use the funding to expand DELiveri®, its proprietary AI-enabled platform for identifying conjugates that can direct RNA medicines to defined cell types, addressing a major constraint in genetic medicine delivery.


RNA interference has transformed the treatment of liver-expressed diseases, but reaching tissues beyond the liver remains a key obstacle limiting the broader potential of the modality. DELiveri addresses this challenge as a groundbreaking technology that screens massive-scale combinatorial libraries of candidate ligands, converting cells to act as molecular radars that detect productive delivery at single molecule resolution. This high throughput data is analysed by agentic AI to decode the resulting structure-activity data and identify conjugates capable of carrying siRNA into target cells.

Undecimal is initially applying the DELiveri platform in renovascular diseases, which pose significant unmet clinical need. Existing treatments of these indications largely address symptoms rather than the underlying etiological factors. Targeted siRNA delivery holds the potential to bring the digital-like precision of genetic medicines, enabling durable, target-specific silencing of the disease-driving pathways.

The round was co-led by 4BIO Capital and IQ Capital, with participation from Verve Ventures, Harel Tech, Entree Capital, Kerna Ventures and Saras Capital. The funding will be used to further development of the DELiveri platform, progress Undecimal’s renovascular programmes and enable expansion of the team at the Company’s laboratories based at the Cancer Research UK Cambridge Institute.

Undecimal has entered several research collaborations with big pharma companies, which are yet to be disclosed.

The Board of Directors comprises representatives of 4BIO Capital, IQ Capital and Harel Technologies, together with co-founders Dr. Yaniv Erlich and Shaul Ilan. Alongside the financing, Verve Ventures joins the Board as an observer.

“The hard problem in RNAi was never the silencing, it was getting the molecule to the right cell,” said Dr. Yaniv Erlich, CEO and Co-Founder of Undecimal Bio. “Our in-vivo validated DELiveri platform can screen large chemical spaces at an unprecedented pace, generating massive data for our legions of AI agents to decipher the structure-activity relationship and score the best candidates. We are excited to bring these advances to develop the next generation of siRNA therapeutics for the benefit of patients.”

Contacts

Notes to Editors

For further information please contact:

Zyme Communications
Lily Jeffery
Tel: +44(0)7891 477 378
Email: lily.jeffery@zymecommunications.com

Undecimal Bio
Dr. Yaniv Erlich
Email: contact@undecimalbio.com

PolyPeptide Group: Provisional interim result of the public tender offer of Samsung Biologics Co., Ltd.

PolyPeptide Group / Key word(s): Tender Offer

PolyPeptide Group: Provisional interim result of the public tender offer of Samsung Biologics Co., Ltd.

13-Oct-2026 / 07:10 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.


Media Release – ad hoc announcement pursuant to Art. 53 LR

Provisional interim result of the public tender offer of Samsung Biologics Co., Ltd.

Baar, Switzerland, 13 October 2026 – Samsung Biologics Co., Ltd. (“Samsung Biologics”), through its direct subsidiary Samsung Peptide AG (“Samsung Peptide”), today published the provisional interim result of its public tender offer (the “Offer”) for all publicly held registered shares of PolyPeptide Group AG (“PolyPeptide”) (SIX: PPGN).

The main offer period of the Offer ended on 12 October 2026, at 4:00 p.m. Swiss time. According to the provisional interim result as published by Samsung Peptide,

  • the participation of Samsung Peptide and the persons acting in concert with Samsung Peptide amounts to 29,123,892 PolyPeptide shares in aggregate, corresponding to 87.92% of the issued share capital and voting rights of PolyPeptide (participation rate); and
  • 29,014,418 PolyPeptide shares were tendered into the Offer until the end of the main offer period of the Offer, corresponding to 87.59% of the issued share capital and voting rights of PolyPeptide and 87.88% of all PolyPeptide shares to which the Offer relates (success rate).

The interim result that has been published today by Samsung Peptide is provisional and is available at https://samsungbiologics.com/offer. The definitive interim result is expected to be published on 16 October 2026. The provisional and the definitive end result of the Offer will be published after the end of the additional acceptance period (see below).

According to the provisional interim result as published by Samsung Peptide,

  • subject to confirmation of the preliminary numbers in the definitive interim result, the offer condition pursuant to section B.7.1(a) (Minimum Acceptance Rate) of the offer prospectus of Samsung Peptide dated 31 August 2026 (the “Offer Prospectus”) has been satisfied; and
  • in addition, the offer condition pursuant to section B.7.1(d) (No Material Adverse Effect) of the Offer Prospectus has also been satisfied.

The Offer remains subject to customary offer conditions, including the receipt of regulatory approvals in certain jurisdictions as well as the removal of the transfer restrictions and voting limitations from PolyPeptide’s articles of association and the election of the persons nominated by Samsung Biologics to the board of directors of PolyPeptide by resolution of an extraordinary general meeting of PolyPeptide. PolyPeptide has invited for an extraordinary general meeting to be held on 26 October 2026 to resolve on these matters.

According to the provisional interim result as published by Samsung Peptide, if the Offer is declared successful (zustande gekommen) in the definitive notice of the interim result, the additional acceptance period of ten (10) trading days for the subsequent acceptance of the Offer will commence on 19 October 2026 and end on 30 October 2026, 4:00 p.m. Swiss time, in accordance with section B.6 (Additional Acceptance Period) of the Offer Prospectus.

 

Contact

PolyPeptide Group AG
Strategic Marketing and Corporate Communications
Laura Rosso
mediateam@polypeptide.com
T: +41 43 502 0580

PolyPeptide Group AG
Finance / Investor Relations
Tim Brandl
investorrelations@polypeptide.com
T: +41 43 502 0580 
 

About PolyPeptide

PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-pre-clinical to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with significant exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, please visit polypeptide.com.

@PolyPeptide — follow us on LinkedIn

About Samsung Peptide and Samsung Biologics

Samsung Peptide is a direct subsidiary of Samsung Biologics. Samsung Biologics and PolyPeptide have concluded a transaction agreement on 17 July 2026 regarding the Offer. Samsung Peptide is acting as the formal offeror of the Offer. Samsung Biologics (KRX: 207940.KS) is a leading Contract Development & Manufacturing Organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing. With a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II in Korea, and 60,000 from the acquisition of a manufacturing facility in Rockville, Maryland, U.S., Samsung Biologics holds total global manufacturing capacity of 845,000 liters. Samsung Biologics has also secured land for Bio Campus III, laying the groundwork for future capacity expansion to support next-generation therapies and emerging modalities. Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity. Samsung Biologics’ global manufacturing and commercial network spans Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. Samsung Biologics is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health. For more information, please visit https://samsungbiologics.com. 

Legal Notice and Disclaimer

No Offer / Offer Restrictions

The information in this media release is for informational purposes only. It does not constitute, or form part of, any offer or invitation to purchase, sell, exchange or issue, or any solicitation of an offer to sell, purchase, exchange or subscribe to, any registered shares or other securities of PolyPeptide or any other person, nor shall it form the basis of, or be relied upon in connection with, any contract in relation thereto. This media release is not part of Samsung Peptide’s publication of the provisional interim result of the Offer or any other publication, communication or other documentation of Samsung Peptide or Samsung Biologics relating to the Offer, including without limitation the Offer Prospectus (the “Offer Documentation”). Terms and conditions of the Offer have been published by Samsung Peptide and Samsung Biologics in the Offer Documentation. Shareholders of PolyPeptide are urged to read the Offer Documentation, which is available at https://samsungbiologics.com/offer.

This announcement is not for publication, release or distribution in any country or jurisdiction in which it would be considered unlawful or otherwise violate any applicable laws or regulations, or which would require Samsung Peptide or Samsung Biologics to change or amend the terms or conditions of the Offer in any way, to make an additional filing with any governmental, regulatory or other authority or take additional action in relation to the Offer. Full Offer restrictions can be found in Samsung Peptide’s Offer Prospectus at https://samsungbiologics.com/offer.

Forward-looking Information and Statements

This media release has been prepared by PolyPeptide and includes forward-looking information and statements concerning the outlook for the Group’s business. These statements are based on current expectations, estimates and projections about the factors that may affect the Group’s future performance. These expectations, estimates and projections are generally identifiable by statements containing words such as ‘expects’, ‘believes’, ‘estimates’, ‘targets’, ‘plans’, ‘projects’, ‘outlook’ or similar expressions. There are numerous risks, uncertainties and other factors, many of which are beyond PolyPeptide’s control, that could cause the group’s actual results to differ materially from the forward-looking information and statements made in this media release and that could affect the group’s ability to achieve its stated targets. Although PolyPeptide believes that its expectations reflected in any such forward-looking statement are based upon reasonable assumptions, it can give no assurance that those expectations will be achieved.

Except as otherwise required by law, PolyPeptide disclaims any intention or obligation to update any forward-looking statements as a result of developments.

 

Additional features:

File: 20261013_PolyPeptide_Media Release_Tender Offer


End of Inside Information


Language: English
Company: PolyPeptide Group
Neuhofstrasse 24
6340 Baar
Switzerland
Phone: +41435020580
E-mail: mediateam@polypeptide.com
Internet: www.polypeptide.com
ISIN: CH1110760852
Valor: 111076085
Listed: SIX Swiss Exchange
EQS News ID: 2414494

 
End of Announcement EQS News Service

2414494  13-Oct-2026 CET/CEST